Vorbereitete Ausführungen
Operator
Good day, and thank you for standing by. Welcome to the Bavarian Nordic Third Quarterly Report for the 9-month period ended 30 September 2026. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Anders Hjort, Head of Investor Relations. Please go ahead.
Anders Hjort
Management
Thank you. Welcome to Bavarian Nordic's Q3 2026 Results. Now turning to Slide #2. I assume you are all familiar with the forward-looking statement. If not, I suggest you become familiar with it. Then turning to Slide #3, just shortly in terms of the agenda for today that we will cover. First of all, we'll go through the key highlights, turning to Travel Health and Public Preparedness, a bit about the pipeline and our commercial performance, and we'll finish up with the financial and the outlook for 2026 and then, of course, also the Q&A.
So I'll now hand over the mic to CEO, Tarja Stenvall.
Tarja Stenvall
Management
Thank you, Anders. Good morning and good afternoon, everyone, and a warm welcome also from my side. This is my first earnings call for Bavarian Nordic, and I'm very pleased that we can report another quarter of strong performance, providing a really solid foundation for Bavarian Nordic's next chapter.
Before going into the numbers, let me share shortly some of my first thoughts as a new CEO. First of all, I am very excited to have joined Bavarian Nordic, and I look forward to leading the company into the next phase of growth. I'm also looking forward to getting to know all of you on this call and through our wider investor engagement. Many of you may already be familiar with my background, and that's what you can expect from me. Having served close to 30 years in large global pharmaceutical companies, including leading the vaccines business, my focus has been on growing and transforming businesses, building long-term partnerships with governments, health authorities and then importantly, making clear choices about where to invest and grow.
I've now been with the Bavarian Nordic for about a month, and naturally, I am still in the listening and learning phase. I spent much of the time with our teams at our sites, with our partners, key stakeholders, but this has left me already with some observations. Firstly, I see speed and agility driven by purpose. People here solve problems without waiting for direction. They have a sense of urgency driven by shared purpose of making life-saving vaccines available to more people. Secondly, I see a delivery under pressure with a real learning culture.
Challenges surface early, and there's a strong appetite to keep improving. They are really hungry to learn. And then finally, but very importantly, I see as well deep expertise and trusted relationships. We have deep knowledge of infectious diseases and a strong network with governments and public authorities we work with. This trust have obviously been built over many years, and I do see it as a real asset to build on. Bavarian Nordic has a good foundation and an encouraging momentum to build on. Together with our leadership team and the Board, we've started to identify the key questions we need to explore in depth over the coming months to sharpen our strategy, such as, how do we fully capture the growth potential in travel health, especially in rabies and the Vimkunya launch and strengthen our position in the key markets such as the U.S.
How do we deepen our partnerships with governments to build greater long-term predictability in Public Preparedness? And then with demand clearly growing strongly, how do we build a manufacturing and supply network that supports our growth efficiently and competitively? Then how do we build on our vaccine expertise and platform to scale the business, both organically and through business development and acquisitions? The objective is simple, to make clear choices about where we focus our efforts and investments to create long-term value. We will share our strategic priorities in the first half of 2027, including our approach to capital allocation. In the meantime, we will remain fully focused on keeping our momentum and delivering on our commitments. Then turning to the Q3 results. For the first 9 months, revenue was just under DKK 4.9 billion, representing reported growth of 2%.
Adjusting for the discontinued partnerships and foreign exchange, organic growth was over 9%. The EBITDA margin was exceptionally strong, close to 35%, also reflecting the phasing of R&D and commercial investments in Q4. Travel Health grew 22% in the third quarter and 24% in the first 9 months. If we exclude discontinued partnerships, growth was over 30%. The main driver is continued momentum in rabies, especially in the U.S., but across geographies, supported by the ongoing launch of Vimkunya and the rest of the portfolio. Public preparedness is in line with our expectations and remains above our annual base level. We secured around DKK 2.4 billion for 2026 and secured around DKK 900 million for 2027. That includes our new 4-year contract with the U.K. government, a really good example of the longer-term partnerships we want to build.
Our financial position is strong. We completed the first tranche of our share buyback in October, and we are starting a second tranche of up to DKK 150 million today. We're maintaining our 2026 outlook, revenue of around DKK 6.1 billion, including approximately DKK 4 billion from Travel Health and EBITDA margin of around 32%. In summary, Q2 was another quarter of strong performance, reflecting the strength of our business, solid execution and our continued ability to deliver on our commitments. I want to recognize the dedication and efforts of our teams across Bavarian Nordic whose contributions have been instrumental in delivering these results.
With this overview, I will hand over to Henrik, our CFO, who will take you through the performance and the business in more detail. As you have heard or actually read in the announcement this morning, Henrik has taken a decision to step down as our CFO this coming spring. We've initiated a search, and I'm confident we can do a smooth transition. Although Henrik is not going anytime soon, I already want to recognize his big contribution for Bavarian Nordic and also on my onboarding that is, of course, still ongoing.
Henrik, please?
Henrik Juuel
Management
Yes. No, thank you very much, Tarja. Good to have you here at your first earnings call really. And let's not spend too much time on my situation. This is about the quarter, but I can only say there's absolutely no drama involved with my desire to step down as CFO. Absolutely not. It's done in a good manner, and I'm sure we will secure some good handover and transition to my successor and to Tarja as well. So let's focus on the quarter this time here. As Tarja said, very strong numbers we have just reported this morning here. And I will spend a little time on the next slide here, looking at first our Travel Health business and then Public Preparedness after that.
So let's start with Travel Health that demonstrated extremely high growth numbers. 32% for the quarter and 34% for the 9 months, if we adjust for the discontinued partner business we used to have with Valneva and Dynavax. So very, very strong growth. To a large extent, driven by continued strong momentum within our rabies business, but also supported by the continued launch of Vimkunya, our chikungunya vaccine and actually also by TBE when we look at TBE on a 9-month basis. If we dive into the Rabies business, then we have seen continued very, very strong market growth across markets, but in particularly outspoken in the U.S. market, which we have seen growing by 36% first 9 months compared to prior year.
Here, you need to understand that it has actually been an accelerating growth. In the beginning of the year, we saw closer to the 20% growth year-over-year, but that has right now on a monthly basis, has accelerated up to around 50% growth. But on a 9-month basis, 36% growth on the rabies business. So very, very strong market demand. I will come back to on one of the next slides in a moment what really drives that. And that has, of course, as we are the market leader, that market growth has a significant impact on our revenue, and we delivered 39% revenue growth on a 9-month basis.
U.S. explained a lot of it, as I said, but we also see significant growth in several European markets, and we start to see the markets we took back from Valneva actually also contributing to the growth of our rabies business. If we then turn to tick-borne encephalitis, our Encepur vaccine, then we have to acknowledge that this year has been a challenging year for our TBE business. We entered the year with relatively low shelf life, which made it a real challenge for our commercial organization to sell into wholesalers and distributors. We have since managed to increase the shelf life. We are not fully home yet, and we continue to work to increase the shelf life. And that has caused periods with supply constraints, and it has caused quarters with disruption. But we are very, very happy that when we look at this business on a year-to-date basis, we have actually delivered a 9% growth.
Due to a tremendous effort by our commercial organization, we have maintained our market share. But it's obvious that when we look at the quarter-by-quarter, we have seen positive quarters. And now in the third quarter here, we actually saw negative growth due to some of the challenges we are facing. But over the year, 9% growth, I think we can be very happy with that given the situation we were in. We are right now leaving the TBE season, and our issues should hopefully be resolved or they are resolved right now so that we are ready to enter into the next season starting spring next year.
Let's spend a little more time on rabies as it explains so much of our growth at the moment. So if we turn to the next slide to talk a little about the underlying growth drivers for the continued strong growth of the rabies market. And here, let's focus on the U.S., which is the key contributor to the growth. I think what we are seeing right now in the U.S. is that rabies is endemic in the U.S. and the areas where you see increased rabies activities are just expanding that you -- that is evidenced by some of the monitoring that the U.S. CDC is doing. Several hotspots have been identified in the U.S. in different states with elevated rabies activity.
And it has also been seen that the rabies is spreading to more animal species. It used to be mainly bats, but now it's also other types of animals as well. And that, combined with people spending a lot of time outdoor, gives a lot of many more situations that you usually have with human to animal encounters and that drives what we call the exposure vaccinations. So when people are in contact with rapid animals in the nature, you have to immediately go to the emergency clinic and get vaccinated. And as this is a deadly disease, there's a lot of media attention around these statistics. And that, again, that media attention creates a demand for vaccinations ahead of any risks. So that is the pre-exposure segment of the market that is, therefore, also seeing a quite significant increase. So very, very strong demand driven by the endemic situation in the U.S. at the moment.
We get a lot of questions around, is this a sustainable situation we see or what's going to happen going forward. I think, first of all, I think we have to be honest and say it's a difficult market to forecast in as not only is the market increasing, it's the growth in itself has been accelerating. So we are, of course, looking into how we can forecast this better going forward. But as we sit here right now, we see no signs that the market should decline again. We are dealing with animals that are infected by rabies in the nature. So it's much more difficult to control than an outbreak in human people that you can actually vaccinate. So, so far, no signs that the market should suddenly decline again.
Let's turn to the next slide, which talks about one of our other growth drivers. That is our chikungunya vaccine, Vimkunya, which we have now launched in most of Europe and in the U.S. as well. I think we have -- on a 9-month basis, we have now delivered DKK 151 million, and as you will recall, we are targeting DKK 200 million for the full year. We have seen so far very good performance in several European markets. Germany in particularly has actually exceeded our expectations. I think where we are still challenged is in the U.S. market, where we -- to be honest, we are not living up to our own expectations yet. But what we have seen is the U.S. taking a rather conservative approach to the recommendation. And at the same time, the recommendation from ACIP has not yet been confirmed in the MMWR publication.
So it does give us some short-term headwinds still in the U.S. to be resolved. We are though quite confident that the U.S. will eventually become one of our key markets also for this product here. This is a disease, chikungunya, that is just in its infancy, if you ask us. We have seen even last week, we saw local transmission of this disease in Switzerland. So the mosquito that is spreading this type of disease is spreading into many more territories. And therefore, we do believe that there is a very significant future potential in this area.
So turning to the next slide, and let's talk about the other business like we have, our Public Preparedness business. We have -- in the third quarter, we have delivered on the orders that we have secured already. So performance in line with our expectations, approximately DKK 1.9 billion. We are targeting DKK 2.5 billion for the full year, and we have already secured DKK 2.4 billion of those by contract. So we need still to close a small gap in terms of contracting, but we are very confident that, that is going to happen as well.
Remember, when we entered the year, we regarded this year to be a more normalized year with no mpox impact as we saw in the 3 to 4 previous years. And therefore, we lowered our expectations to this year. But despite that, we have managed to get some good large contracts, enabling us to deliver DKK 2.5 billion this year, which is above our normal business base level of DKK 1.5 billion to DKK 2 billion. So again, strong execution on Public Preparedness. We're very happy that we, earlier this year, managed to -- in Europe to extend the label to include children aged 2 to 12, and we have some more ongoing trials that will eventually help us to further expand the label for this vaccine.
On the next 2 slides, I just wanted to share a couple of recent developments within our Public Preparedness business. And I think on the first one here, we talk about the initiative taken by the International Coordination Group on Vaccine Provision, which is hosted by the WHO. They are taking an initiative to create a global emergency stockpile that in particularly low middle-income countries can tap into. And we are very proud that we were awarded a contract to supply 150,000 doses into the stockpile. And on top of that, we decided to donate another 75,000 doses of our vaccine. So this will all be delivered this year into the stockpile so that the ICG, the International Coordination Group can allocate these according to the needs. So a very, very good development, securing vaccine access to low and middle-income countries.
On the next slide, another good development. We have recently announced that we were awarded a contract with the U.K. government. The very interesting thing with this contract is that it's a multiyear contract. It's a 4-year contract to supply mpox, smallpox vaccine to the U.K. government. We do not have many of those, and it has been the cause of some of the volatility we have seen in our Public Preparedness business in the past has been that governments typically wouldn't commit beyond 1 year. So this is a very good sign of our long-standing partnership with the U.K. government.
Enough about the commercial business, then a very quick update on our pipeline, which you will see on the page now. Overall, all our programs, they are on track. We are running post-approval committed studies on chikungunya. We are developing the cell line manufacturing process for our MVA smallpox/mpox vaccine, which is now running in Phase II. And we are also in Phase II with an equine encephalitis vaccine development fully funded by the U.S. government. And then we do have 2 preclinical assets, Lyme assets, where we anticipate to go into the clinic in '28 and then our EBV preclinical assets, which we still believe should enter the clinic this year. So all in all, in line with plans. And hopefully, the 2 preclinical assets are going to generate an interesting news flow going forward as well.
So now let's turn to some of the financials, and we will start with the commercial performance. And as Tarja alluded to, she did highlight some of the numbers here. If you just look at the reported numbers for the quarter, it's 0.6% growth. But if we adjust for discontinued partnership, it's actually more than 9% for the quarter, 7% full year. But more interestingly, it is to look at the individual business legs where we saw Travel Health growing 32% when adjusted for third-party products and 34% on a 9-month basis. So strong growth from our travel business and solid execution on our public preparedness business. I've already addressed some of these, the rabies business, 38% growth. Encepur, 9% growth despite the challenges that we have been facing. Vimkunya, 258%, it's obviously a new launch. So all in all, very strong growth. We also saw Vivotif growing strongly. Vaxchora, small product that is typically driven more by outbreaks and specific orders. So all in all, on a 9-month basis, nearly DKK 4.8 billion.
So let's turn to the full P&L. We already touched upon the top line. If we then turn to the gross profit, we delivered 52% for the quarter. It's up a couple of percentage points compared to last year, driven by a good product and country mix. If you look into the quarter in itself, then there were things contributing positively, and that is definitely product and country mix, a lot more sales into the U.S. and a lot more rabies sales. But then on the more challenging front, we also had some challenges when we changed from TBE campaign manufacturing first half of this year.
And during the summer, we were switching over to rabies. That changeover took longer than anticipated, which meant that basically we couldn't manufacture for 3 to 4 weeks. And that, of course, also has an impact on the gross margin. But it's all you can say, absorbed within the numbers that you see here and still we come out with a quite a solid gross margin here. And we are right now up and running with rabies according to the plans again.
Total operating costs, somewhat below last year's level for the quarter and mainly explained by some of the initial Vimkunya launch costs that were included in the third quarter of last year and then also some costs associated with the takeover attempt last year as well. If we take it all down to the bottom line, then we see we are delivering an extraordinary 34.4% EBITDA margin, very strong EBITDA margin, also above the, you can say, the stated ambition level of 25% to 30% that we have announced previously. When we compare to last year, we have to remember that in the Q3 of last year, we sold a priority review voucher, which gave us DKK 810 million in income. If you deduct that from the EBITDA, then you're actually comparing to a 28% EBITDA last year. So we are up 6 percentage points in terms of profitability as well. On a 9-month basis, also close to 35% EBITDA and an EBITDA of DKK 1.7 billion. So very, very strong performance on the P&L this year.
Next slide deals with the cash flow. And of course, strong EBITDA typically means you're also delivering a strong cash flow. And if we look at the quarter in itself, it was DKK 809 million cash flow from operating activities. Cash flow from investment activities, these are mainly placement of cash into securities, so really not as such, consuming the cash, giving us a free cash flow of more than DKK 500 million. The cash flow from financing activities, the DKK 170 million, that's all explained more or less by the share buyback programs we have done in the -- during the quarter. And still after the share buybacks, we are delivering net cash flow of DKK 372 million. So very, very strong cash flow generation as well. If you look at the cash flow for the 9 months, you have to remember that we -- during that period of time, we paid back the last milestone to GSK, EUR 70 million, which is impacting the cash flow from operating activities. If you obviously deduct from that, you will also see that it's a very strong performance for the full 9 months.
Final page, I will just use that one to remind you of our current outlook for the year. We are, after upgrading both our Public Preparedness business and our Travel Health business, we are now projecting DKK 6.1 billion in revenue, DKK 3.4 billion from our Travel Health business and DKK 2.5 billion from Public Preparedness, and we are targeting an EBITDA for the full year of 32%.
So with that, I will give the word back to the operator and ask for questions, please.
Operator
[Operator Instructions] And this one comes from Thomas Bowers from SEB.
Fragen und Antworten
Thomas Bowers
Analyst
A few questions from me here. So maybe just to kick off with your '26 guidance. So can you maybe comment a little bit on the implied Q4 revenue outlook? So Travel Health revenue approximately, well, DKK 500 million plus/minus. So that implies a decline of 20% or maybe 10% if you adjust for the partner product sale. So what actually explains this implied slowdown also given that maybe Encepur should maybe recover a little bit at least?
And then on Vimkunya, so sales, very strong this quarter with, I guess, almost double the quarter-on-quarter. So -- and I understand Germany is appearing to be the key driver here. Can you maybe just explain sort of the differences between or across Europe on the uptake and maybe how we should think about the pace of that market development in Europe going forward?
And then just the last question, just on capacity. So exceptional Rabipur demand, obviously, but I'm a little bit curious on manufacturing capacity. So will that still be sufficient if you continue that strong growth going into '27, also without compromising any Encepur supply here? Or is any need for additional investments to increase that production flexibility, I guess?
Tarja Stenvall
Management
Okay. To start, Henrik, will you take the first question?
Henrik Juuel
Management
Sure. I will do that. Thank you, Thomas, for the questions here. So let me address the first one on the guidance. I think, first of all, don't forget what our guidance says approximately, and we are guiding DKK 3.4 billion on Travel Health. There can, of course, be variations to that. It is an approximate guidance. And then don't forget the seasonality as well. And if you look at the EBITDA margin and the Q4 there, I think the reason for that is that we are targeting a lower EBITDA margin for the Q4 in itself, first of all, expected lower revenue compared to the previous 9 months that's implied from our guidance, obviously, but then also back-end loaded investments into R&D projects and sales and marketing.
But I think we are -- I think we can fairly say that we are probably on the conservative side, but nothing that should require that we should change our guidance at this point in time. So I hope that was sufficient on that one, Thomas.
Thomas Bowers
Analyst
Yes. Thank you.
Tarja Stenvall
Management
Maybe I'll say a few words on Vimkunya. You asked specifically about the Europe. Then saying about the U.S., and Henrik highlighted that we have some access topics at the moment. Still, I think it's important it's a disease in infancy in the U.S. as well. So we continue working hard as well in terms of raising awareness, making sure that the safety profile of our vaccine is well known as well, knowing that there was a vaccine that was withdrawn from the market.
And when it comes to Europe, obviously, Germany as often is the kind of #1 market in Europe, and we put effort was there, and we are very pleased how we see the takeoff in terms of travelers and the doctors adapting the vaccine as well as working markets around. We also start seeing cases of chikungunya. I think the other week, we heard that there was a case in Southern France, for example. So I think the disease even in Europe is in infancy at the moment. So as usual, in launch, we go a bit step by step, and we're learning as we are moving forward, but we are very pleased in terms of how we see the progress in Europe at the moment.
I don't know, Henrik, if you have...
Henrik Juuel
Management
No, maybe I can just add one thing, and that is when you look at the quarterly numbers on Vimkunya, don't expect sort of a smooth curve because we are launching into many countries, and therefore, it can be a little lumpy as you -- when you sort of supply into the whole supply chain. So it will not -- probably not be a smooth curve -- one day when we look back on how we entered this market here. But as we sit here right now today, we are confident that we will meet the soft guidance we have provided of DKK 200 million.
Tarja Stenvall
Management
And of course, U.S. plays important role in the Europe business. And then does that answer?
Henrik Juuel
Management
Yes, there was one on capacity.
Tarja Stenvall
Management
Yes, then the capacity, I will also say that looking at the organization, we've been able to really deliver well on this growing demand. U.S., we've had no supply issues this year at all. And we've done sort of quick wins as well smartly, I call it printing manufacturing to really keep up with it. And obviously, being a life-saving vaccine and us playing such an important role with a high market share in many countries, that's a real priority for us going forward and making sure with the forecast for the future that we have the right manufacturing and supply capabilities that can work effectively and deliver.
And we have to estimate and see with the demand and what type of investments we need to put into that place. And then the question about Encepur and Rabipur, maybe you want to elaborate on this one as well. Henrik?
Henrik Juuel
Management
Yes. I think you explained it pretty well, Tarja. I think it's -- what we have done right now is that we've done everything we can in terms of easy wins. We did during the summer break here, we changed the batch sizes. We're going to do that again during the Christmas shutdown. And I think we are quite confident that, that will enable us to supply into expected demand during '27. But of course, we are constantly looking at this. And as we talked about it before, we need really to understand where this rabies market in the U.S. is going. And then it might require additional investments that are not the quick wins, but we might need to also invest to make sure we can -- even the years beyond '27, we can still supply to the demand in the market as this is a life-saving vaccine.
Operator
[Operator Instructions] And this one comes from Romy O'Connor from Kempen.
Romy O'Connor
Analyst
I also had one on Vimkunya. So with the U.S. uptake expectedly slower, I was just wondering if you can clarify a bit more on what the conservative approach you mentioned meant from the CDC. And regarding timelines for the MMWR publication, what could the 2027 ramp then look like if that wouldn't happen? And maybe more of a general question. So with the second tranche of the buyback underway and also the strong cash position, I was just wondering what we should expect to learn about how you'll weigh investments in the existing portfolio, maybe potential M&A and further buybacks in the strategic presentation in the next half of 2027.
Henrik Juuel
Management
Thank you. Yeah.
Tarja Stenvall
Management
Thank you. Do you want to elaborate a bit on the U.S. side and then I can talk about the investments.
Henrik Juuel
Management
Yes. So thanks, Romy. What I mentioned regarding the conservative approach by the U.S. government on the recommendation is there is currently a recommendation in the U.S. that if you travel to a country with a current outbreak, you should get chikungunya, you should get vaccinated. The conservatism comes in how do you determine a current outbreak. And in the U.S., that is defined by a U.S. citizen coming back to the U.S. with chikungunya, which is very, very late in the process. And what it actually means that if you look up on the CDC's website today, there are only 3 countries listed with current outbreaks.
The similar European side, I believe there are more than 15 countries listed because here, they actually monitor ongoing real outbreaks. So it's a rather conservative definition of an outbreak in the U.S. And then, of course, combined with the fact that they have not yet confirmed the ACIP recommendation in the MMWR publication, and that is normally more of an administrative task. It doesn't mean we can't sell, but it means that some of the customers are reluctant to buy because they are breaking sort of their normal routines. They normally look up in the MMWR and to find the recommendations. And if they can't, they say, okay, then we are not buying. So it's just providing a short-term headwind to us.
We do believe that this is something that will over time be resolved. It will take time, of course, to work with the government. We know that U.S. is one of the markets where you do now and then have outbreaks of chikungunya as well, and we think that will eventually also convince people of the need to have a vaccine available in the market and to have a good recommendation in place. So that was the question on Vimkunya.
Then we had a question on the buybacks and -- you're right. We are doing buybacks at the moment. Sorry, there's some noise in the background. I don't know how it comes in here. Okay. I'll continue. We are right now, as we have reported, we just finished the first tranche of the DKK 750 million buyback, and we this morning announced the start of the next. We are in a very, very solid financial position. We have reported despite the share buybacks, nearly DKK 3 billion of cash. So we have plenty of cash at the moment. We are -- if you look in our R&D, you talked a little about investing in our current portfolio and inorganically as well.
Part of our money really goes into what we call life cycle management to make sure that we improve the position of all our products. And a lot of that is really some of the label expansion opportunities we have to make sure that our products are covering as broad as possible in the market. So that's one of the areas where we invest. And then we have the M&A part, which remains part of our strategy. And we are constantly looking at opportunities, but we are also extremely picky. We only want something that is generating revenue. That's our current focus at least, that is generating revenue from day 1. It's not diluting our profitability and that fits in with our commercial infrastructure.
So we have decided that right now, we are striking a good balance between preserving cash to act on opportunities when the right ones are there and then paying money back to the shareholders with the current share buybacks.
Tarja Stenvall
Management
And maybe to build on Henrik's answer, at the moment, we are working in this moment is a good momentum to take a look at the opportunities that we have, I would say, a lot around us where do we stand by investing in our current business and how can we make that grow and get the full potential out of it and then also look at M&A at the same time. And we're planning to come out then in the next spring with the guidance in terms of capital allocation going forward.
Operator
[Operator Instructions] And this one is from Hakon Hemme from Danske Bank.
Hakon Hemme Jørgensen
Analyst
Welcome and congratulations on the new role. A couple of questions from my side. On rabies, at the Q2 call, you explained that the wholesaler inventory buildup had amplified growth. And your Q3 sales are now up 37%, both on quarter-on-quarter and year-over-year, as you mentioned. So while your commentary now seems more focused on underlying demand. Can you elaborate on that? Was the Q3 performance purely driven by underlying demand? Or did the wholesaler inventory movements also contribute? And now -- and just a follow-up on M&A because you say that you are constantly looking at M&A. But with you, Tarja now in the role and Henrik preparing to leave, are you still actively pursuing M&A opportunities in this transition period? Or has it become less of a priority until a full team is ready?
Henrik Juuel
Management
Yes. Let me take the rabies one. I think what we said during the Q2, you're right, Hakon, thanks for the question, by the way. We did say that the wholesaler inventory probably amplified the growth. And I think what is happening when a market is growing as fast as we are seeing here with rabies, as we talked to earlier, in the beginning of the year, we saw 20% growth, but it's actually been accelerating up to 50% growth. Then what is happening at the wholesaler level, they typically try to have a certain number of days on inventory. So they constantly also increase their holdings, amplifying the whole situation. And that happened during Q2. It probably also happened here during Q3. That is simply just an effect of such a rapid increase.
And it's difficult for us to separate the effects really because we're talking 2 different numbers. The market growth that we're looking at with close to 40% on the 9 months, that is in market data. There's a time lag to ours, and we, of course, record what we sell into the wholesalers. But I think this amplification is simply an effect of such increased demand as wholesalers, they typically define their inventory levels as a days of sales compared to expected future sales. So I think that was on the rabies. Then we had the M&A, Tarja?
Tarja Stenvall
Management
M&A questions, yes. So I would say, yes, M&A continues to be part of our strategy as it's been in the past year. And I would say it's been the DNA of Bavaria and the whole Travel business has been built on the M&A. When I then talk about sharpening the strategy going forward in next year, we gave our last guidance '24 longer-term guidance. So I think it's a good momentum right now with sales that are exceeding expectations to a little bit sit back and make sure that we are truly focused on the right priorities to be able to drive existing business in terms of targets for M&A activity as well. So then more about that in the next year. But yes, it continues to be part of our strategy.
Operator
We're going to take the next question. This one is from Peter Hugreffe from Nordea.
Peter Ankersen
Analyst
Peter Hugreffe from Nordea. And again, also welcome to you, Tarja. Two questions. Firstly, I can see that you quoted in Danish media that you are talking about a strategic change, which, of course, is interesting. So can you maybe give us a little bit of comfort around this strategy review? What is the direction? What is it that you're looking for and so on? That's the first question.
Then secondly, your predecessor, one of the last things he did was to up the Public Preparedness outlook from DKK 1.5 billion to DKK 2 billion -- to actually DKK 2 billion. And now I can see that either it's forgotten or you have retracted on that part. So -- is it DKK 2 billion as a base? Or is it -- are we back to DKK 1.5 billion to DKK 2 billion?
Tarja Stenvall
Management
Well, thank you, Peter, and thanks for welcoming me to my new role. I go back on your question about this strategy. I think we're doing well. And I said it's a very strong and solid base to continue the business. When you grow with the speed and change that Bavarian Nordic has done, they created another business besides the MVA-BN platform. You can see that there's many things ongoing and people are committed. They take a lot of action. I think it's a good way to make sure we channel the energy exactly to the right place. That's why I'm calling sharpening the strategy and make sure that we really focus on the right priorities under existing business as well as looking at the M&A opportunities so that we really scale the platform in terms of growing that platform that we can then absorb more growth, either organically or inorganically.
We have a very young commercial organization still. It has been there only a few years. So it's also making sure that on that side, we focus on kind of what matters the most in terms of understanding the markets, focusing on the markets that are the most critical going forward. I don't know if that gives you a clear view, Peter...
Peter Ankersen
Analyst
Yes. So for me, it sounds more like you're focusing on how can you execute on your strategy rather than kind of a review of the current, but maybe semantics.
Tarja Stenvall
Management
Yes, maybe this is semantics. I think you need to take holistically each sector of our business, whereas the public preparedness, there is the business of travel health and then you look at the M&A side. So you look at holistically the 3 pillars, and you make it clear on the direction going forward.
Peter Ankersen
Analyst
Got it.
Henrik Juuel
Management
Great. And thanks, Peter, for the questions here. To the other one on Public Preparedness, we have not officially changed our guidance on that one. So our medium-term guidance. It remains DKK 1.5 billion to DKK 2 billion. I think what Paul said is that looking at what we have achieved so far, I think he said we are probably closer to the DKK 2 billion, but we have not officially changed that one. I think this year is a good example. We are delivering DKK 2.5 billion. So that could argue, of course, for going above the DKK 1.5 billion to DKK 2 billion, but it's also still very sensitive to a few big orders.
So next year, as Tarja alluded to, we will come out with a sharpened strategy and next -- end of next year, our midterm financial targets are also sort of expiring, which we announced at the Capital Markets Day in '24. So in connection with that, it would be natural to sort of also restate what is the base business level for the public preparedness. So far, it stays at the DKK 1.5 billion to DKK 2 billion, but we are very happy that even this year, in a year where there is no material impacts, we are delivering DKK 2.5 billion, so significantly above that base business level.
Peter Ankersen
Analyst
Got it. Can I have a follow-up on the public preparedness?
Henrik Juuel
Management
Sure.
Peter Ankersen
Analyst
So it's just when I compare with where we are today compared with last year, then you have secured SEK 900 million and last year, it was DKK 1.1. So I mean, is it fair to assume that you are almost kind of at the same level for '27 based on what you see right now? Or is there any kind of lumpiness in what you have secured already now compared to last year? Just trying to understand kind of the trajectory. Does that make sense?
Henrik Juuel
Management
No, I think it's fair. I think if you asked us 2 months ago, we probably say we are ahead of last year. But if you look at it right now, we are probably more or less same place as we were this time last year with DKK 900 million, I wouldn't say in the bank, but at least orders secured. So we feel that is -- we are in a good position also to deliver within the ambition level for next year.
Operator
We are now going to take the next question. And this one is from Benjamin Jackson from Jefferies.
Benjamin Jackson
Analyst
Just one for me this time. Just interested to know whether you have any color you can provide on how European rabies market would react to a new entrant in that market. Obviously, one of your competitors hoping for approval towards the end of this year. How do we think about the spillover of that on either price or volumes to you guys? And is there anything else worth flagging about contracting timelines, et cetera? So any thoughts around that would be super useful.
Tarja Stenvall
Management
Well, thank you. Thank you, Benjamin, for the question. What I've seen so far, I think our rabies position in kind of key markets is really strong if I look at the U.S. and Germany. We've been a good partner in terms of supply constantly. And the vaccine has been market for a long time with a very, very strong data. So in terms of the competitor and what they can offer, I think we're in a very good position to keep the leadership and the strong position in the market going forward. And at the moment as well, it is a growing market. So our job as well is to make sure that we increase the awareness and make sure that people would get vaccinated as they should going forward.
Does that answer your question, Benjamin?
Benjamin Jackson
Analyst
Yes, I guess, that makes sense.
Operator
There are no further questions for today. I will now hand the call back to Tarja Stenvall for closing remarks.
Tarja Stenvall
Management
Well, thank you, everyone, for attending the call and for your questions and for welcoming me as well. With this, I hope you as well a very nice weekend. Thank you.
Operator
Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect.